STVN
Stevanato Group S.p.A.NYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
26.88
PEG
1.46
P/B
2.19
P/S
2.75
EV/EBITDA
12.72
DCF Value
$-9.42
FCF Yield
0.5%
Div Yield
0.4%
Margins & Returns
Gross Margin
29.0%
Operating Margin
16.5%
Net Margin
11.8%
ROE
9.7%
ROA
5.7%
ROIC
6.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $343.3M | $47.2M | $0.17 |
| FY 2025 | $1.14B | $134.3M | $0.49 |
| Q3 2025 | $303.2M | $36.1M | $0.13 |
| Q2 2025 | $280.0M | $29.7M | $0.11 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IT
Exchange
NYSE
Beta
0.62
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.